Congestive heart failure: Treat the disease, not the symptom—Return to normalcy  by Buckberg, Gerald D.
appear in many dictionaries. Its antonym is unhealthy or
away from normal. The word restore is also absent from
the literature. This is defined as “will bring things back
to normal.” I use the term restore and hope its under-
standing creates a paradigm shift that may change cur-
rent treatments of pathologic conditions.
CHF is a change from the normally elliptical left ven-
tricular shape to a spherical dilated muscle, in which the
fiber angle for normal contraction is lost and the natural
tightness between excitation and resulting contraction
becomes abnormal. The collagenase architecture sur-
rounding the muscle, including nerves and vessels,
becomes diminished by this distention. Dilatation rais-
es metabolic needs and may cause ischemia because of
abnormal flow distribution.1
The distended, dilated muscle initiates a biochemical
reaction in the renin-angiotensin and sympathetic sys-
tems. Abnormal levels of angiotensin are present in the
renin-angiotensin system to combat distention and pro-
duce hypertrophy of working muscle. The sympathetic
nervous system is stimulated to increase blood pressure
by vasoconstriction to supply organs and enhance heart
rate to maximize output. Additionally, aldosterone lev-
els are elevated to cause peripheral constriction to main-
tain blood pressure and enhance scarring. Reduced
urine output results from diminished renal blood flow
and sodium retention, and a change in collagen content
of the heart produces dilatation by collagenase stimula-
tion through distention.
The medical treatments of these consequences are
angiotensin-converting enzyme inhibitors (limiting col-
lagen breakdown), β-blockers (decrease sympathetic
tone), spironolactone (decreases aldosteronism and
fibrosis), and diuretics like furosemide (Lasix) to
enhance urinary blood flow and produce decompression
of retained fluid. These treatments prolong life
expectancy in patients with CHF and help to reduce the
classification of CHF from class IV to class II-III. This
reflects a moderate enhancement in activities and a
rightward shift of the mortality from the 50% 5-year
mortality, yet it allows an ongoing downward trend in
which, at present, 50% of persons with CHF now live
for 8 years. The end result is the same overall mortali-
ty, with fewer symptoms and prolonged health care.
Hospitalizations are frequent in patients with class III
and class IV CHF, approximately 2 million in 1 year,
Pathology is the dilemma that physicians confront dailyin patient care. The consequences of any distortion of
structure become the symptoms of the disease created by
abnormal processes. Treatment is directed toward allevi-
ation of these results that “remodel away” from normal
structure and biochemistry. This confrontation over
symptoms occurs in the health care community (medi-
cine, surgery, pharmacology, medical devices, and
through annual health care costs). Medical students can-
not wait to leave their learning curve–established normal
principles. To many, these are an astounding roadblock
between the basic and clinical areas. The obligatory
study of normality is a “brief hurdle” they must pass on
the real road to becoming a physician. Fundamental basic
sciences are thought to reflect the unimpeachable camp
of the “preclinical school.” The motivational objective is
to deal with the dilemma of the sick patient.
The purpose of this report is to show that departure
from normality and lack of focus on its importance are
very expensive and less effective ways to deal with
pathologic conditions. The result of this focus on abnor-
mality caused by disease is an explosive development
of drugs, operations, machines, and health care person-
nel to minimize the physical and biochemical derange-
ments of such diseases. A prominent example is con-
gestive heart failure (CHF), which affects 4.9 million
persons in the United States. The disease constitutes
loss of the normal elliptical ventricular architecture, to
produce a dilated spherical ventricle with limited con-
tractile and filling capacities. The consequences are
fatigue, pulmonary congestion, associated arrhythmias,
repeated hospitalizations, and eventually death.
The pathologic derangement is called remodeling due
to heart diseases in which the blood flow, valve, and
muscle itself are damaged. This term remodel is used
extensively in medical and surgical circles to define the
diseased state, but the definition of this word does not
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and approximately 50% of such patients need rehospi-
talization. The cost today is $100 billion per year to
Medicare and private insurance providers. By 2020 the
cost will exceed $1 trillion per year, as the number of
patients older than 65 years will double. This astro-
nomical expense has stimulated the National Institutes
of Health, Health Care Financing Administration, phar-
macologists, and drug companies to deal with the
symptoms of CHF. There is marginal interest in the dis-
ease itself: the role of changing the anatomy of the
dilated ventricle.
The electrical approach to the sphere includes a
wrapping of the diseased muscle, called cardiomyo-
plasty, to prevent dilatation. Electrical defibrillators are
implemented to treat arrhythmias caused by this dis-
tention. Right ventricular pressure and then pulmonary
artery pressure (reflected from right ventricular pres-
sure) are monitored to detect early signs of pulmonary
congestion caused by decreased left ventricular empty-
ing. This may limit early rehospitalization before CHF
advances to a later stage. Additionally, biventricular
electrical pacing restores normal septal contraction as
excitation/contraction delay follows distention. These
abnormalities occur in both normal muscle (that can
recover) and abnormal muscle. The recovery reflex in
electromechanical abnormality is corrected by bypass-
ing slower conduction with direct septal, right ventric-
ular, and left ventricular stimulation.
Surgical treatment follows the same rightward shift
of decreasing mortality, yet the downward curve per-
sists. Revascularization alone enhances survival, and
long-term mortality relates to preoperative ejection
fraction. At 10 years, survival was 20% at an initial
ejection fraction of 25% and about 40% at an initial
ejection fraction of 35%.2 Augmented blood flow
relieves angina, but the downward mortality trend per-
sists. A similar prognosis follows valve replacement or
repair for valve insufficiency in dilated or ischemic car-
diomyopathy. Restoring mitral valve competence by
valve replacement (without coronary disease) in
patients with an ejection fraction of less than 40%
yields a 60% mortality at 10 years3; after valve repair,
the 5-year mortality is 50% in patients with ischemic
and dilated mitral incompetence.4
This symptomatic treatment displaces the mortality
curve to the right by altering the downward trend.
Patients require frequent visits from nurses to start
inotropic drugs to improve cardiac output and pre-
vent rehospitalization. Exercise capacity in patients
who have a dilated heart remains limited. Repeated
hospitalizations are required to treat recurrent CHF.
These limitations account for an astounding health
care cost.
Alternate surgical methods to deal with the fatiguing
heart include mechanical displacement of the failing
ventricle with a left ventricular assist device. These
devices involve expensive initial costs, can become
infected, and can generate clots because of the absence
of an endothelial covering. They reduce the symptoms
of CHF but do not function for a prolonged period.
They are not available in all centers and require sub-
stantial monitoring. The final step, transplantation, is
limited by restricted organ availability and subsequent
rejection and immunosuppressive treatment to avoid
rejection. The treatment for rejection itself includes
complications, such as coronary artery disease and
tumor formation.5,6
The diagnostic dilemma
The approach to the symptoms versus the disease is
most evident during characterization of the diagnosis
of the pathologic abnormality that reduces left ventric-
ular function and produces CHF. Attention is directed
toward how blood is ejected, rather than toward the
underlying left ventricular volume and shape responsi-
ble for diminished heart function. Everyone accepts
that a low ejection fraction is abnormal and recognizes
that the heart must deal with this to maintain cardiac
output by dilating. Fatigue is recognized as a limitation
of decreasing reserve by ventricular dilatation.
Unfortunately, attention is seldom paid to the left
ventricular volume itself, the spherical underpinning of
CHF. This provides a classic example of this funda-
mental dilemma, a misunderstanding of the disease
despite routine assessment of the left ventricle by ven-
triculography. This critical information is routine dur-
ing cardiac catheterization to evaluate for ejection frac-
tion, yet determining left ventricular size has not
achieved the critical role it deserves in the CHF entity.
The right anterior ventricular view of left ventricular
function is routine or sometimes excluded because of
echocardiographic study. Biplane ventriculograms that
clearly characterize both ejection fraction and global
volume are seldom obtained. Magnetic resonance imag-
ing (MRI) measures left ventricular size and is available
but not used in most institutions. The current pattern of
left ventricular evaluation persists despite important
knowledge of the value of ventricular volume made
available since 1987 from White and associates7 (Fig 1).
There is a close correlation between increased volume
and progressive mortality that is independent of evaluat-
ing ejection fraction in many patients (Fig 2).7
The value of end-systolic volume indices is unknown
to many physicians and surgeons, even though their
value has been recognized. Gaudron,8 Di Donato,9 and
their associates reinforced the concept by showing how
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both changing and altering the left ventricular size
affects muscles whose fiber orientation is changed sur-
gically to create a more normal ellipse. This geometric
approach excludes muscle affected by myocardial
infarction that cannot recover because of akinesia. 
The value of left ventricular end-systolic volume index
(LVESVI) versus ejection fraction is further character-
ized by Yamaguchi,10 Vanovershelde,11 and their col-
leagues. Unfortunately, these fundamental manuscripts
are not in the database of many leaders in the treatment
of CHF. Data developed in CHF clinics and worldwide
symposiums to deal with the manifold symptoms of
CHF persist with this disease. Our patients sustain
exhaustive and unfathomed tests that characterize the
consequence of low output syndrome from the damaged
muscle. The concept of sphericity is recognized but
rarely calculated. There is emphasis on the diastolic
spherical index rather than on systole when ejection frac-
tion occurs. Articles on CHF that do focus on the spher-
ical heart often do not emphasize the essential contrac-
tion and suction properties of the ellipse.
The National Institutes of Health has exhibited extra-
ordinary interest in CHF. Many of its conceptual lead-
ers focus on the special position of individual knowl-
edge and the “unique responsibility of a certain gene of
CHF.” A broad extent of genetic factors is stimulated
by the “process of CHF,” but the capacity to focus on a
single factor may reflect a real limitation of focal
knowledge in understanding the disease.
The first step is to understand the true central
theme, the spherical dilated ventricle as the causative
factor. As physicians, we must recognize that remod-
eling only enlarges our understanding of this abnor-
mal area. The symptom purveys each patient study of
regulated responses and captures our diagnostic and
therapeutic interest. The importance of the novel
objective to restore the geometry to a more normal
ventricular shape should be recognized. Rebuilding
fundamental fiber orientation structure will allow
more normal muscle function. This is the true end
point of our therapeutic approaches. Treat the dis-
ease, not the symptom. 
This criterion of unifocalization is known as knowl-
edge, and this is defined as “taking apart” or differentiat-
ing or analyzing approaches. Of course, the result will be
an astounding expertise in one aspect of CHF, but where
is the communication between other aspects and this
observation? In and of themselves, they will not and can-
not deal with any interconnected factors. The synthesis of
key points of the aforementioned factors are then “put
together” for integration. This solution is called wisdom.
These concepts are drawn together by a vast degree of
underlying knowledge. To do this, we must separate our-
selves from the isolated expertise and then use a broad
understanding of all aspects of individual factors toward
the solid solution that is implemented.
Our role is to control symptoms after normal geome-
try is restored, not to displace correction of the prob-
lem. Conventional approaches deal with the vessels
supplying blood to normal muscle, the secondary
changes of the ventricle that cause valve insufficiency,
but not with the abnormal ventricle directly.
At this time, these architectural changes can occur by
surgical correction. In that surgical correction process,
we cannot superimpose more intraoperative damage
during restoration. Unless intraventricular injury from
Fig 1. The relative risk for death after myocardial infarction,
depicted as the relationship between LVESV and survival.
The volume index is approximately 50% of end-systolic vol-
ume, or 25 ± 10 mL/m2. (From Colucci WS, editor. Atlas of
heart failure: cardiac function and dysfunction. 2nd ed.
Philadelphia: Current Medicine, Inc; 1995, 1999; adapted
from White et al.7 Reprinted with permission.)
Fig 2. The relationship between LVESVI and ejection frac-
tion. There is correlation, but great overlap (r2 = 0.29. These
values were described by Di Donato and Dor (Centre
Cardiothoracique de Monaco, 2000) in patients undergoing
restoration.
poor protection is avoided, preventable changes will
markedly limit the influx of medical/surgical participa-
tion in this process and thereby exclude the use of sur-
gical procedures that correct CHF.
The evolution
The history of our organized escape from under-
standing normalcy is the 1-year allocation of time for
the learning of normalcy (ie, the first year of medical
school). This is followed by a 3-year drive to see patho-
logic conditions, understand them, learn them, and
treat them. This information is used for the remainder
of medical school training and throughout the physi-
cians’ medical lives. The remodel end point becomes
our starting point. Some think it is a failure to return to
the point of initial escape—the normal heart.
In the heart, for example, we learn about constriction
for systole, as described by Harvey, and about dilata-
tion for diastole, also described by Harvey. The concept
of twisting and untwisting are unknown to many physi-
cians and surgeons, even though they are precisely how
the heart ejects and sucks to fill. These concepts date
back to the Greeks, with Erasistratus and then Galen.
They were discarded by Harvey, who was simply incor-
rect. Borelli described the heart as a rope with a vortex
or spiral of fibers and clarified that ejection was like
twisting a rope to wring out blood. Anatomists like
Vesalius, Mall,12 and others showed that muscle struc-
ture for twisting and untwisting occurs. Only with MRI
can we now characterize this more precisely. Despite
these factors that define normalcy, they are relatively
unknown to those who practice medicine, surgery, and
treat CHF throughout the health care community.
Instead, the ejection fraction is fundamental, with a
near complete absence of either measuring the LVESVI
or, more importantly, understanding its meaning when
its vital value is given along with the conventional ejec-
tion fraction recording. The focus is on a specific num-
ber (ie, ejection fraction) rather than on understanding
the concept of how the ellipse works to improve func-
tion and where fiber angle (not ejection fraction) is crit-
ical. This focus defeats our progress. Many experts
know calcium, ionic balance, muscle fiber kinetics,
electrophysiology, molecular biology, and neuroen-
docrine responses. Each factor is important, but coali-
tion of these entities is needed.
The present: A new focus on the akinetic heart
Surgeons and cardiologists read but do not listen to
the geometric solutions suggested by Jatene and Dor
and Cooley to return ventricular shape toward an ellip-
tical form. Others in the CHF community are unaware
of these efforts. To some, this seems like an “all too
simple solution.” Perhaps that is the answer, for nature
is simple. It is scientists who are complicated, as sug-
gested by Torrent-Guasp (personal communication).
We need to learn from understanding normality. The
way to understand normality is to remove the current
focus only on the pathologic remodeled aspect caused
by disease. 
The anatomic dilemma of CHF is a dilated ventricle.
In coronary artery disease, especially with anterior
infarction, there is replacement of the anterior wall and
septum with either a scar or akinetic muscle with mar-
ginal salvage of epicardial regions after reperfusion.
There is no aneurysm, but a nonfunctional muscle is
left in place. The disease of CHF is related to dilatation
of the remaining remote muscle. Its compensatory
hypertrophy becomes diminished if coronary artery
disease affects vessels supplying functional segments.
The later onset of mitral regurgitation is due to
increased ventricular distention. A restrictive valve
defect develops with or without annular dilatation and
compounds the symptoms. The conventional approach
to restoring blood supply and mitral valve competence
must become amended by rebuilding left ventricular
geometry.
The surgical approach in this spherical formation is
to exclude the noncontractile area with a patch or direct
suture to delete apical and septal loss. The septum
always must be excluded if it is diseased. This is a
novel surgical approach, especially with nonscarred
muscle, as occurs frequently with reperfusion with tra-
beculated muscle salvage without function. This results
in alteration of left ventricular shape to restore an ellip-
tical formation. This resultant geometric change
reduces wall stress by limiting radius and increasing
thickness. Simultaneously, there is increasing deforma-
tion of strain produced by more normal muscle fiber
orientation.
An alternate objective: The restored ventricle
CHF occurs in 4.9 million patients in the United
States and 69% have coronary artery disease. Among
them, 90% have a myocardial infarction, which results
in loss of regional contraction and thereby altered car-
diac structure/function relationships. The geometric
consequence is loss of the free wall and underlying
septum. Left ventricular ejection predominantly is
caused by longitudinal shortening relying on obliquely
oriented fibers. There is conversion of normal elliptical
shape with oblique fiber orientation (where 15% short-
ening causes 60% ejection fraction) to a spherical
chamber where a more transverse fiber orientation
reduces contractile forces (ie, 15% fiber shortening
causes 30% ejection fraction) in remote viable mus-
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ventricle, especially with dyskinesia, is uncommon.
The “open artery” concept produces a wave front of
death starting in the endocardium. Recent MRI studies
by Bogaert and associates24 confirm the epicardial via-
bility and underlying necrosis of the inner two thirds of
the left ventricular wall. A family of damage develops,
with 80% to 90% of contractile muscle in the endo-
cardium and midmyocardium lost, covered by a veneer
of epicardial salvage to prevent the extensive remodel-
ing with aneurysm formation. However, the incidence
of CHF rises progressively, as the akinetic (noncon-
tractile) left ventricle remains and progressive remote
dilatation occurs. The infarcted noncontractile section
remains akinetic and still involves the free wall and
septum, but operatively has a normal surface from epi-
cardial salvage. We must now focus on this akinetic
segment.
Surgical technique
Ventricular reduction surgery is termed surgical ven-
tricular restoration and follows the format of estab-
lished approaches to ventricular scar established by
Dor, Jatene, and Cooley and now used in aneurysm
surgery. The procedure changes the spherical left ven-
tricular characteristics of CHF to a more normal ellip-
tical shape to lower wall stress and enhance thickening
of remote viable muscle, through increasing deforma-
tion (ie, torsion), by producing a more helical fiber ori-
entation. 
The straightforward surgical approach, before infarct
revascularization (ie, open coronary artery), was with the
nonfunctional transmural scar that dimpled during left
ventricular decompression (venting) to clarify the “free
wall” part of injured muscle. The primary approach was
toward aneurysms (bulging segment). More recently,
these approaches have been applied to thin akinetic
(nonparadoxical) scars, as well as conventional
aneurysms.20-22 There has been restricted approach to
the septum. Aspiration defines only transmural scar, but
it does not describe the nonfunctional region that causes
CHF. Attention to only the thin wall limits septal exclu-
sion, as occurred in only 12% of Mickleborough’s
cases,23 compared with exclusion of 100% in an
approach described by Dor25 and Jatene.20 Mickle-
borough achieved a 6% increase in ejection fraction after
restoration of akinetic hearts without septal exclusion
versus Dor’s 18% increase in ejection fraction by
excluding the septum and 40% reduction in size.25
Because of thrombolysis or percutaneous translumi-
nal coronary angioplasty, there is now salvage of epi-
cardial muscle, preventing dyskinesia (ie, paradox), yet
MRI evidence of necrosis of the inner shell of midven-
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cle.13 MRI studies show that myocardial stress and
strain reduce and decrease contractile shortening in
remote myocardium (ie, from 15% to 10%) so that
ejection fraction is lowered accordingly.14 Progressive
dilatation of remote muscle further reduces its contrac-
tile force and increases CHF and mortality, depending
on ultimate left ventricular size.7,8,10,15,16
The prognosis of CHF after myocardial infarction is
related to the volume and shape changes of the left ven-
tricle. Regional infarction of more than 30% of left
ventricular circumference causes progressive dilatation
of remote viable muscle that tends to convert the nor-
mal elliptical left ventricular shape to a sphere.17 The
normal LVESVI of 25 mL/m2 increases to exceed 60
mL/m2 when more than 40% of muscle becomes non-
functional. However, an LVESVI of more than 45
mL/m2 often progresses to cause clinical CHF.7,8,15-18
This onset of clinical symptoms may develop 6 months
to 3 years after acute myocardial infarction as the
remote muscle dilates.8,15 However, the propensity for
CHF can be predicted by LVESVI measured 90 min-
utes after myocardial infarction.15 Assessment of left
ventricular size at 12-month intervals after myocardial
infarction is predictive of CHF and mortality.16 In
patients first assessed at a time remote from the acute
episode, a resting LVESVI of more than 60 mL/m2
reflects a threshold likely to be associated with subse-
quent cardiac mortality.15
The surgical approach to scar is established, with 6%
of patients who have coronary bypass surgery also
undergoing aneurysmectomy. In the past, the conven-
tional surgical decision to address the segment intraop-
eratively was based on how much scarred noncontract-
ing segment collapsed (ie, dimpled) during left
ventricular decompression, signifying that transmural
scarred segment. Initial surgical procedures only
excluded the bulging segment, as described by Cooley
and associates18a in 1959—the linear approach that did
not exclude the aneurysm. There was negligible
approach to the akinetic left ventricle, because exclu-
sion of only anterior wall, without the septum, did not
improve CHF symptoms.19 More recently, the entire
thinly scarred region has been excluded, including the
free wall and septum, through the work of Jatene20 in
1984, imbricating the scarred region, Dor, Kreitmann,
and Jourdan21 in 1984 (intraventricular patch), Cooley
and associates22 in 1989 (endoaneurysmectomy), and
Mickleborough and colleagues23 in their article in this
Journal.
Currently, thrombolytic treatment and percutaneous
angioplasty for acute myocardial infarction have
decreased aneurysm formation so that the scarred left
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tricular and endoventricular muscle persists.14 Akinesia
is evident on ventriculogram, echocardiogram, and
MRI, yet the epicardial surface, surgically, is normal
with occasional trabecular scar. The akinetic wall does
not collapse during left ventricular venting, yet the
decision for exclusion of the nonfunctional free wall
and septum is made preoperatively, through nonfunc-
tion documented by dynamic assessment (ventriculo-
gram, echocardiogram). 
The left ventricle can be opened with conventional
cardioplegic approaches (used for coronary bypass
grafting and mitral valve repair when needed) to define
an endocardial scar. Absence of visible scar is not prob-
lematic, because the aortic clamp is removed to allow
the heart to beat so that digital palpation (not vision)
allows decisions about separation between noncon-
tracting free wall and septum and furthermore docu-
ments viable contracting remote muscle (ie, inferior or
lateral wall and septum) that was made dysfunctional
by myocardial stretching. This digital (not visual) sep-
aration allows a circumferential Fontan stitch to be
placed to reduce cavity size and create a “surgical
neck” for exclusion of noncontracting free wall and
septal nonfunctioning regions. The ellipse is restored
by inserting an oval patch (Dacron, pericardium, septal
flap), or by using interrupted sutures to deal with the
nonscarred, nonfunctional, more muscular suture bed.
The technique of placing sutures into muscle rather
than scar may include interrupted sutures with pledgets
for hemostatic security. This mechanical technique is
firmly established surgically, as the method mirrors, pre-
cisely, what is used for valve replacement. Here, the oval
orifice within the ventricle, without moving parts,
becomes substituted for the valve orifice when a prosthe-
sis is placed in patients with valve disease. The surgical
oval site and suture techniques are commonplace. There
is no risk for air embolism in the beating open heart, as
this technique has been used for many years with antiar-
rhythmic approaches during intraventricular surgery.
The improved myocardial protection afforded dur-
ing restoration by either conventional cardioplegia or
the beating state becomes coupled with rebuilding a
more normal elliptical geometry to augment ejection
fraction intraoperatively and postoperatively. Con-
sequently, mechanical support is infrequently needed
in these high-risk patients with severe left ventricular
dysfunction.
Another factor, which is important in evaluating the
role of surgical ventricular restoration, is that medical
therapy for treating CHF has advanced significantly.
Randomized, placebo-controlled blinded studies have
shown that β-blockers, when added to digoxin, diuret-
ics, and angiotensin-converting enzyme inhibitors,
decreased mortality by at least 30%, with annual mor-
tality rates for patients with class II and III CHF on β-
blockers less than 15%. In addition, there is similarly
impressive reduction in frequency of hospitalizations
for cardiovascular diseases and decreased progression
for CHF. Furthermore, trials of coronary bypass graft-
ing with left ventricular failure in which ejection frac-
tion is less than 35% show low operative mortality
(~3%) and 65% to 75% 5-year survival.2,26 Despite
these encouraging survival results, approximately 50%
of patients have CHF at the 5-year follow-up interval,26
and 10-year mortality is 60% to 80% if ejection frac-
tion is either less than 35% or less than 25%.2
In 1998, an international cooperative effort of sur-
geons and cardiologists to investigate the surgical vas-
cular restoration (surgical ventricular restoration) pro-
cedure was organized to include leading centers in the
United States, Europe, Asia, and South America. Nine
centers have collected and shared information on 439
consecutive patients undergoing the surgical ventricu-
lar restoration procedure.27 The team is called
RESTORE (rebuilding normal elliptical architecture).
The mean (± SD) age of these patients was 63 ± 10
years; baseline ejection fraction was 28% ± 10% with
a median LVESVI of 110 mL/m2. Akinesia was present
in 67% and dyskinesia in 33%. One hundred one of the
patients (23%) also had mitral valve repair and 96%
had bypass grafting. Only 7% required intra-aortic bal-
loon pumping. Operative mortality was 5.7%, estimat-
ed 1.5-year mortality was 10%, and rehospitalization
for CHF was 7%. Postoperative ejection fraction was
39% ± 12.6% (an increase of 10.5 ± 0.5 percentage
points) with a median LVESVI of 68 mL/m2 (a 34.5-
mL/m2 decrease).
The left ventricular shape, independent of ejection
fraction, defines prognosis after surgical treatment to
restore a smaller size and increase elliptical shape dur-
ing rest and exercise. The operative mortality was only
5.7% in 439 patients in a recent series, yet the large left
ventricular shape, even after successful surgical treat-
ment of the three components in CHF (coronary bypass
grafting, mitral valve repair, and left ventricular shape)
determined long-term prognosis after follow-up over
10 years in all survivors (Fig 3).
Studies of left ventricular shape in the RESTORE
patients, which supplement the extensive experience of
Vincent Dor and Marisa Di Donato, show surgical
restoration of size will reduce LVESVI from 110 to 68
mL/m2. Our collaborative surgical/medical team has
taken the steps suggested in my editorial in 1998,28 in
which restoration becomes a component of surgical
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treatment of the failing akinetic heart. The extent of
postoperative reduction is related to initial LVESVI.
Clearly, the extent of irreversible changes from chron-
ic dilatation leading to remote muscle scar will become
greater as the volume of viable muscle becomes larger.
Conversely, the incidence of CHF and mortality with-
out restoration exceeds 30% in 1 year if LVESVI is
more than 60 mL/m2 immediately after myocardial
infarction.15 These LVESVI signposts immediately
after infarction can be useful to both treat CHF and
predict CHF in left ventricles with systolic dysfunction
and increased volume. A change in geometry may
occur in postinfarction patients undergoing revascular-
ization with a large ventricle before CHF symptoms
develop.
Restoration: Hibernation and mitral valve
The surgical rebuilding of left ventricular volume
excludes the infarct region that can be dyskinetic, aki-
netic, or significantly hypokinetic from epicardial via-
bility from recent revascularization.14 The restoration
value of exclusion becomes even more apparent if
LVESVI is greater that 75 mL/m2 and positron emis-
sion tomography or dopamine viability exists in a non-
functioning or severely hypokinetic scar that is conven-
tionally thought to be hibernating. Revascularization
alone does not change left ventricular volume11 in large
ventricles (>75 mL/m2) so that the potential area of
regional hibernation does not recover. In small hearts
(<75 mL/m2) the delay of increased contraction of the
infarcted region is 1 to 6 months. Only then increased
regional shortening of remote muscle follows to
improve ejection fraction. In contrast, exclusion of the
nonfunctional area restores immediate contractility
(independent of initial volume)25 because the left ven-
tricular size is reduced surgically, the remote muscle
develops a reduced radius and becomes thickened, and
ejection fraction rises immediately after the restoration
procedure. 
Currently, there is a “biphasic approach” toward
either the mitral valve or the ventricle. Mickleborough
and associates23 deal with the left ventricle and do not
change the mitral valve. In contrast, Bolling and asso-
ciates4 changed the mitral valve and did not change the
ventricle. They reported reduced sphericity, increased
New York Heart Association function, and low opera-
tive mortality, but the 5-year results showed approxi-
mately 50% mortality. Left ventricular volumes were
not reported, and I presume that changes in cardiac size
accounted for the late mortality. These results paral-
leled late valve replacement (aortic and mitral) results,
with approximately 60% mortality if ejection fraction
was less than 40%, even though the surgical procedures
provided a perfectly competent valve.3
It seems clear that the large ventricle determines ulti-
mate prognosis. Mitral insufficiency is a dynamic pro-
cess that worsens with exercise, as the left ventricle
dilates and changes tethering of the chords and papil-
lary muscle to decrease coaptation. Certainly, left ven-
tricular restoration improves mitral valve function
(81%), yet some insufficiency persists.23 Consequently,
the residual insufficiency can produce a secondary
increase in cavitary size that can potentially offset the
value of restoration unless both mitral and ventricular
aspects are corrected. The surgical approach to CHF is
therefore a trilogy to deal with the vessels, valve, and
ventricle.
Evaluation changes
Classic symptoms of CHF (fatigue or shortness of
breath) can be characterized most clearly through phys-
iologic measurements of peak oxygen uptake—how
cardiac output increases to deliver flow to meet meta-
bolic needs with exercise. This physiologic measure-
ment of peak oxygen consumption correlates with pro-
gression of, at rest, left ventricular size/time in patients
with CHF (independent of resting ejection fraction or
volume) and progressive mortality.29 After convention-
al medical treatment (angiotensin-converting enzyme
inhibitors, β-blockers) mortality is high at 18% if oxy-
gen consumption increases, and doubles to approxi-
mately 40% if oxygen consumption falls during
sequential yearly measurements.16,29 Of equal impor-
tance to resting shape, the dynamic shape with exertion
determines exercise capacity.30 Oxygen consumption
rises if the left ventricle becomes more elliptical
(reduced LVESVI) and falls if the left ventricle
becomes more spherical (increased LVESVI). The
Fig 3. Relationship between preoperative LVESVI (mL/m2)
and survival to 10 years. Note increased long-term survival if
LVESVI is more than 120 mL/m2. These patients underwent
surgical ventricular restoration at Centre Cardiothoracique de
Monaco by Dor.
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measurement provides a physiologic marker of ventric-
ular mechanics for CHF progression. A more elliptical
shape during systole improves fiber orientation to aug-
ment ejection (ie, MRI twisting).30 Similarly, early
diastolic filling needed to augment venous return for
cardiac output is enhanced after increased ellipse dur-
ing exercise; demonstrating untwisting on MRI will
improve diastolic suction.31
Approximately 30% of patients with an ejection frac-
tion of less than 35% in a recent series had moderate
(2+) mitral regurgitation with increased spherical
chamber formation.27 Exercise capacity (ie, peak oxy-
gen consumption) is reduced if there is only mild (1+)
mitral regurgitation under resting conditions.32 Mild
mitral regurgitation at rest restricts oxygen consump-
tion during exercise and thereby accounts for the
increased CHF symptoms during exertion. This physi-
ologic measurement may be useful in preoperative pre-
diction of need for mitral valve repair in patients under-
going coronary bypass alone or in combination with a
restoration procedure.
Arrhythmic approaches
The predominant cause of late death in CHF is either
progressive hemodynamic deterioration or sudden
death. Distention is a key factor to late arrhythmia
development. In the past, correction of electrophysio-
logic defects responsible for sudden death included
cryotherapy to the unexcluded muscle and endo-
cardiectomy. This method was used by Mickle-
borough23 and Dor,25 resulting in few patients dying of
late ventricular tachycardia. The role of decompression
alone in reducing late arrhythmias is not yet known.
Many surgeons test patients postoperatively by pro-
grammed ventricular stimulation and insert an auto-
matic implantable cardiac defibrillator or use antiar-
rhythmic drugs. Subsequent comparisons will define
which approach is more appropriate.
This geometric change in mechanical muscle forma-
tion markedly diminishes the requirements for electri-
cal treatment of heart failure. Wrapping the muscle,
cardiomyoplasty, is not needed because volume is
diminished surgically. Automatic implantable cardiac
defibrillators are uncommon, due to diminished dilata-
tion and resultant ectopy. Increased pulmonary artery
pressure becomes limited, because function of the left
and right sides of the heart is improved by restoring an
elliptical shape. Consequently, electrical monitoring of
pulmonary artery pressure to avoid rehospitalization
becomes uncommon. The septum of the restored heart
beats spontaneously immediately after the operation if
myocardial protection is adequate.33 Consequently, the
need for biventricular pacing is limited or avoided.
The future
We must more properly measure how the left ventri-
cle functions to eject and fill. This amends standard
clinical signs of dyspnea, fatigue, and edema.
Sufficient twisting for ejection must provide enough
cardiac output to meet metabolic needs during exercise,
while appropriate untwisting for suction of venous
return avoids raised filling pressure to cause lung con-
gestion. These consequences of ejection and filling are
not currently measured but are achievable through eval-
uating peak oxygen uptake during exercise and nonin-
vasive pulmonary artery pressure by echocardiography.
Organized use of these available evaluation methods
can enlarge precision in the extent of CHF and its alter-
ation by treatment.
I have summarized 3 events (Tables I and II) that
reflect a fundamental alteration in how the ventricle is
viewed (ie, change from only fiber shortening to
include evaluation of size and shape), how dysfunction
Table I. Potential CHF changes in diagnosis, treatment, and management
Conventional Alternative
Diagnosis EF ESVI, percent asynergy
Medical treatment CABG + MVR Conventional + surgical ventricular restoration
Evaluation of treatment Symptoms VO2, PAP
The “alternative” pathway means LVESVI and asynergy (noncontractile area) are measured in addition to ejection fraction (EF). Surgical treatment will amend coro-
nary bypass grafting ± mitral valve repair (CABG ± MVR) with restoration. A more precise prognosis will supplant New York Heart Association class with mea-
surements of oxygen consumption (VO2) during exercise and changes of pulmonary artery pressure (PAP) by echocardiogram.
Table II. If restoration is useful, this challenge may
alter the way outcome is evaluated, treated, and mea-
sured in patients with CHF
Introduce to:
Cardiologists Importance of LV size
Surgeons When to alter LV geometry
CHF clinicians Efficacy of exercise VO2 measurements
CHF, Congestive heart failure; LV, left ventricular; VO2, oxygen consumption.
is treated (ie, evaluating how geometric changes of size
complement conventional medical and surgical treat-
ment), and how treatment is evaluated by supplement-
ing symptomatic assessment by measuring peak oxy-
gen uptake during exercise.
These geometric observations on the mechanical
adjustment may reduce the current symptomatic treat-
ment of the consequent disease of a spherical heart. The
surgical restoration of the left ventricular ellipse may
reduce the extraordinary expansion of drugs, surgery,
and electrical devices toward morbidity and mortality
related to focus only on remodeling away from normal.
The mechanical solution of that course needs further
testing. All must recognize the normal cardiac helical
structure, and our interest is to strive to restore the geo-
metric configuration responsible for heart function.
This may augment reserve and may avoid medical, sur-
gical, electrical, and health care costs currently related
to only reducing morbidity. The hope is to separate this
treatment from the present mortality and morbidity end
point, where the disease is left intact, but only modi-
fied. Our central focus may change, but this can occur
only when we begin to understand, and then restore, the
normal structure with its attendant functional counter-
part. Normality, rather than less disease, should prevail
to achieve the solution to CHF.
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